MEI Pharma Inc
MEIP3.070USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
20.46MMarket Cap
LossP/E TTM
More Details of MEI Pharma Inc Company
MEI Pharma, Inc. is a pharmaceutical company, which is engaged in developing cancer therapies. The Company’s pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and prior to its sale (as discussed below), ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib has completed a Phase I trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) in combination with the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (marketed as Venclexta). Voruciclib is also being evaluated in pre-clinical studies to explore potential activity in various solid tumor cancers including in combination with therapies that target the RAS signaling pathway, such as KRAS inhibitors. MEI-344 is a novel drug candidate that inhibits mitochondrial OXPHOS, a fundamental metabolic pathway involved in the production of adenosine triphosphate (ATP) in the mitochondria.
MEI Pharma Inc Info
Ticker SymbolMEIP
Company nameMEI Pharma Inc
IPO dateDec 18, 2003
CEOMr. Justin J. (Jay) File
Number of employees28
Security typeOrdinary Share
Fiscal year-endDec 18
Address9920 Pacific Heights Blvd
CitySAN DIEGO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92121
Phone18583697100
Websitehttps://www.meipharma.com/
Ticker SymbolMEIP
IPO dateDec 18, 2003
CEOMr. Justin J. (Jay) File
Company Executives of MEI Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joshua Riezman
Mr. Joshua Riezman
Independent Director
Independent Director
--
--
Dr. Nicholas R. (Nick) Glover, Ph.D.
Dr. Nicholas R. (Nick) Glover, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Justin J. (Jay) File
Mr. Justin J. (Jay) File
Chief Executive Officer, Chief Financial Officer, Company Secretary
Chief Executive Officer, Chief Financial Officer, Company Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joshua Riezman
Mr. Joshua Riezman
Independent Director
Independent Director
--
--
Dr. Nicholas R. (Nick) Glover, Ph.D.
Dr. Nicholas R. (Nick) Glover, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Justin J. (Jay) File
Mr. Justin J. (Jay) File
Chief Executive Officer, Chief Financial Officer, Company Secretary
Chief Executive Officer, Chief Financial Officer, Company Secretary
--
--
Revenue Breakdown
FY2025
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: 19 hours ago
Updated: 19 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Schornstein (Alexander)
11.87%
Citadel Advisors LLC
5.71%
GSR Growth Investments LP
4.84%
Polar Asset Management Partners Inc.
3.19%
Renaissance Technologies LLC
2.77%
Other
71.62%
Shareholders
Shareholders
Proportion
Schornstein (Alexander)
11.87%
Citadel Advisors LLC
5.71%
GSR Growth Investments LP
4.84%
Polar Asset Management Partners Inc.
3.19%
Renaissance Technologies LLC
2.77%
Other
71.62%
Shareholder Types
Shareholders
Proportion
Hedge Fund
16.94%
Individual Investor
12.75%
Investment Advisor
7.69%
Corporation
4.84%
Investment Advisor/Hedge Fund
1.50%
Research Firm
0.45%
Venture Capital
0.19%
Other
55.64%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
65
3.01M
8.43%
-355.92K
2025Q2
68
2.76M
29.56%
-831.40K
2025Q1
86
2.76M
41.47%
-950.08K
2024Q4
96
2.80M
42.00%
-1.36M
2024Q3
106
2.83M
42.55%
-1.57M
2024Q2
117
2.75M
41.27%
-1.77M
2024Q1
163
2.92M
43.84%
-1.73M
2023Q4
197
3.20M
48.10%
-3.32M
2023Q3
212
3.03M
45.44%
-2.87M
2023Q2
220
2.80M
42.09%
-2.77M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Schornstein (Alexander)
4.37M
12.24%
+2.25M
+106.41%
Sep 09, 2025
Citadel Advisors LLC
634.27K
1.78%
+634.27K
--
Jul 22, 2025
GSR Growth Investments LP
1.78M
4.99%
+1.78M
--
Sep 23, 2025
Renaissance Technologies LLC
132.35K
0.37%
-2.10K
-1.56%
Jun 30, 2025
UBS Financial Services, Inc.
8.25K
0.02%
+1.81K
+28.04%
Jun 30, 2025
The Vanguard Group, Inc.
401.86K
1.13%
-364.00
-0.09%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 14, 2023
Merger
20→1
Apr 14, 2023
Merger
20→1
Apr 14, 2023
Merger
20→1
Apr 14, 2023
Merger
20→1
Date
Type
Ratio
Apr 14, 2023
Merger
20→1
Apr 14, 2023
Merger
20→1
Apr 14, 2023
Merger
20→1
Apr 14, 2023
Merger
20→1
FAQs
Who are the top five shareholders of MEI Pharma Inc?
The top five shareholders of MEI Pharma Inc are:
Schornstein (Alexander) holds 4.37M shares, accounting for 12.24% of the total shares.
Citadel Advisors LLC holds 634.27K shares, accounting for 1.78% of the total shares.
GSR Growth Investments LP holds 1.78M shares, accounting for 4.99% of the total shares.
Renaissance Technologies LLC holds 132.35K shares, accounting for 0.37% of the total shares.
UBS Financial Services, Inc. holds 8.25K shares, accounting for 0.02% of the total shares.
Schornstein (Alexander) holds 4.37M shares, accounting for 12.24% of the total shares.
Citadel Advisors LLC holds 634.27K shares, accounting for 1.78% of the total shares.
GSR Growth Investments LP holds 1.78M shares, accounting for 4.99% of the total shares.
Renaissance Technologies LLC holds 132.35K shares, accounting for 0.37% of the total shares.
UBS Financial Services, Inc. holds 8.25K shares, accounting for 0.02% of the total shares.
What are the top three shareholder types of MEI Pharma Inc?
The top three shareholder types of MEI Pharma Inc are:
Schornstein (Alexander)
Citadel Advisors LLC
GSR Growth Investments LP
Schornstein (Alexander)
Citadel Advisors LLC
GSR Growth Investments LP
How many institutions hold shares of MEI Pharma Inc (MEIP)?
As of 2025Q3, 65 institutions hold shares of MEI Pharma Inc, with a combined market value of approximately 3.01M, accounting for 8.43% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -21.12%.
What is the biggest source of revenue for MEI Pharma Inc?
In FY2025, the -- business generated the highest revenue for MEI Pharma Inc, amounting to -- and accounting for --% of total revenue.
